Explore the poster abstract on precision oncology in the 2024 JMCP supplement.
Testimonials
We’re aiming for meaningful change. Whether making sure insurance coverage reflects the latest science, encouraging automatic biomarker testing when cancer is diagnosed, setting a consistent quality standard, or helping precision medicine become a bigger priority across the health care system, we see incredible potential for improving patient well-being.
Featured Articles
Precision medicine in oncology using actionable molecular biomarkers to guide treatment s
Precision medicine, the customization of health care to an individual’s genetic profile while accounting for biomarkers and lifestyle, has increasingly been adopted by health care stakeholders to guide the development of treatment options, improve treatment decision making, provide more patient-centered care, and better inform coverage and reimbursement decisions. Despite these benefits, key challenges prevent its broader use and adoption.
BACKGROUND: Although precision medicine using genetic information offers significant promise, its uptake and eventual clinical and economic impacts are uncertain.
This analysis addresses an important policy question: “What are potentially transformative strategies and methods to define and measure value at all levels of decision making that are aligned with personalized medicine/precision medicine (PM/PrM)?” To approach this question, we build on our previou
View an AMCP press release on AMCP's Partnership Forum, "Managing Care in the Wave of Precision Medicine. "Precision medicine is no longer emerging, it's happening now," according to Susan A. Cantrell, RPh, CAE, CEO of the Academy of Managed Care Pharmacy (AMCP).
Precision Medicine Resources
Lung cancer is the most common cancer worldwide, with non-small cell lung cancer (NSCLC) accounting for approximately 85% of all lung cancers. The National Institutes of Health estimated that cancer care cost the US $208.9 billion in 2020, $23.8 billion of which was due to lung cancer.
This webinar featured a candid conversation with panelists from AMCP’s Market Insights Roundtable on Bridging the Gaps in Precision Oncology: Opportunities in Non-Small Cell Lung Cancer.
To understand the appropriate and cost-effective use of biomarker-driven treatment selection in NSCLC, AMCP convened an expert panel of managed care stakeholders.
The lack of implementation of predictive biomarkers in clinical practice results in a significant number of individuals with NSCLC not deriving benefits from targeted treatments. Payers have the potential to shape various aspects of the precision oncology pathway, such as addressing biomarker test ordering, utilizing test results to inform treatment decisions, implementing quality measurements, and understanding cost-effectiveness.
Learn how AMCP is helping professionals and stakeholders navigate the application of precision medicine in managed care pharmacy to improve patient outcomes, lower drug costs, end ensure better medication management.
Featured News & Resources
See Full Calendar
National Meetings
Midwest AMCP Chicago Day of Education
National Meetings
Mountain West Pharmacy Summit
Upcoming Events
AMCP offers a wide variety of educational opportunities, from events and webinars to online training.
